The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
대표청구항▼
1. A method of binding an anti-gal antibody to a cancer cell present in a subject comprising: providing an isolated glycoconjugate to a subject that has an anti-gal antibody, wherein said isolated glycoconjugate comprises: a first domain that is a ligand for a receptor on the cancer cell present in
1. A method of binding an anti-gal antibody to a cancer cell present in a subject comprising: providing an isolated glycoconjugate to a subject that has an anti-gal antibody, wherein said isolated glycoconjugate comprises: a first domain that is a ligand for a receptor on the cancer cell present in said subject or an amino acid sequence of an antibody that binds the cancer cell present in said subject; anda second domain that has at least one Gal α(1,3)Gal saccharide synthetically conjugated to said ligand or said amino acid sequence of an antibody, wherein said at least one Gal α(1,3)Gal saccharide is directly joined to the first domain at one amino acid, such that said first domain binds to said cancer cell and said second domain binds to said anti-gal antibody, thereby generating a complex in said subject that comprises said anti-gal antibody, said glycoconjugate, and said cancer cell. 2. The method according to claim 1, wherein the glycoconjugate comprises a ligand for a receptor on the cancer cell. 3. The method according to claim 1, wherein the glycoconjugate comprises an amino acid sequence of an antibody that binds the cancer cell. 4. The method according to claim 3, wherein the amino acid sequence encodes a complementarity determining region (CDR) of the antibody. 5. The method according to claim 1, wherein the first domain is between 3-200 amino acids in length. 6. The method according to claim 1, wherein the first domain is between 5-100 amino acids in length. 7. The method according to claim 1, wherein the first domain is between 8-50 amino acids in length. 8. The method according to claim 1, wherein the first domain is between 10-25 amino acids in length. 9. The method according to claim 1, wherein said at least one Gal α(1,3)Gal saccharide is directly joined to the first domain at a hydroxylated amino acid. 10. The method according to claim 1, wherein a plurality of Gal α(1,3)Gal saccharides are joined to the first domain. 11. The method according to claim 1, wherein said glycoconjugate further comprises a peptide sequence that is recognized as non-self by existing antibodies in the subject. 12. A method of generating a complex that comprises an anti-gal antibody, an isolated glycoconjugate, and a cancer cell in a subject comprising: (i) identifying a subject that has a cancer cell and an anti-gal antibody;(ii) providing to said subject an isolated glycoconjugate that comprises: a first domain that is a ligand for a receptor on the cancer cell or an amino acid sequence of an antibody that binds the cancer cell; anda second domain that has at least one Gal α(1,3)Gal saccharide synthetically conjugated to said ligand or said amino acid sequence of an antibody, wherein said at least one Gal α(1,3)Gal saccharide is directly joined to the first domain at one amino acid, such that said first domain binds to said cancer cell and said second domain binds to said anti-gal antibody, thereby generating a complex that comprises said anti-gal antibody, said glycoconjugate, and said cancer cell. 13. The method according to claim 12, wherein said at least one Gal α(1,3)Gal saccharide is directly joined to the first domain at a hydroxylated amino acid. 14. A method for forming a complex, comprising: (i) administering to a subject a bifunctional binding moiety comprising a first domain that is a ligand for a receptor on a cancer cell or an amino acid sequence of an antibody that binds a cancer cell and a second domain that has at least one Gal α(1,3)Gal saccharide synthetically conjugated to said ligand or said amino acid sequence of an antibody, wherein said at least one Gal α(1,3)Gal saccharide is directly joined to the first domain at one amino acid;(ii) binding said first domain to a cancer cell in the subject; and(iii) binding said second domain to anti-gal antibody in the subject, thereby forming said complex. 15. The method according to claim 14, wherein said at least one Gal α(1,3)Gal saccharide is directly joined to the first domain at a hydroxylated amino acid. 16. The method according to claim 1, wherein the glycoconjugate is a peptide. 17. The method according to claim 12, wherein the glycoconjugate comprises a ligand for a receptor on the cancer cell. 18. The method according to claim 12, wherein the glycoconjugate comprises an amino acid sequence of an antibody that binds the cancer cell. 19. The method according to claim 18, wherein the amino acid sequence encodes a complementarity determining region (CDR) of the antibody. 20. The method according to claim 12, wherein the first domain is between 3-200 amino acids in length. 21. The method according to claim 12, wherein the first domain is between 5-100 amino acids in length. 22. The method according to claim 12, wherein the first domain is between 8-50 amino acids in length. 23. The method according to claim 12, wherein the first domain is between 10-25 amino acids in length. 24. The method according to claim 12, wherein a plurality of Gal α(1,3)Gal saccharides are joined to the first domain. 25. The method according to claim 12, wherein said glycoconjugate further comprises a peptide sequence that is recognized as non-self by existing antibodies in the subject. 26. The method according to claim 12, wherein the glycoconjugate is a peptide. 27. The method according to claim 14, wherein the bifunctional binding moiety comprises a ligand for a receptor on a cancer cell. 28. The method according to claim 14, wherein the bifunctional binding moiety comprises an amino acid sequence of an antibody that binds a cancer cell. 29. The method according to claim 28, wherein the amino acid sequence encodes a complementarity determining region (CDR) of the antibody. 30. The method according to claim 14, wherein the first domain is between 3-200 amino acids in length. 31. The method according to claim 14, wherein the first domain is between 5-100 amino acids in length. 32. The method according to claim 14, wherein the first domain is between 8-50 amino acids in length. 33. The method according to claim 14, wherein the first domain is between 10-25 amino acids in length. 34. The method according to claim 14, wherein a plurality of Gal α(1,3)Gal saccharides are joined to the first domain. 35. The method according to claim 14, wherein said bifunctional binding moiety further comprises a peptide sequence that is recognized as non-self by existing antibodies in the subject. 36. The method according to claim 14, wherein the bifunctional binding moiety is a peptide.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (68)
Su Yi C. (Madison WI) Lee Wong Amy C. (Madison WI), Staphylococcus aureus enterotoxin H and methods of use.
Hook Magnus ; Lindberg Kjell Martin,SEX ; Wadstrom Torkel Mikael,SEX, Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manu.
Hk Magnus (Birmingham AL) Jnsson Klas (Studentvgen SEX) Lindberg Kjell M. (Kornvgen SEX) Signs Christer (Hamnesplanaden SEX), DNA encoding a fibronectin binding protein as well as its preparation.
Maddon Paul J. ; Littman Dan R. ; Chess Leonard ; Axel Richard ; Weiss Robin,GBX ; McDougal J. Steven, DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS.
Hook Magnus (Birmingham AL) Lindberg Martin K. (Upsala SEX) Signas Lars C. (Upsala SEX) Wadstrom Torkel M. (Lund SEX) Froman Gunnar (Upsala SEX), Fibronectin binding protein as well as its preparation.
Hook Magnus ; Lindberg Martin Kjell,SEX ; Signas Lars Christer,SEX ; Wadstrom Torkel Mikael,SEX ; Froman Gunnar,SEX, Fibronectin binding protein as well as its preparation.
Burnham Martin Karl Russel,GBX ; Chopra Ian,GBX ; Critchley Ian Alfred,GBX ; Knowles David Justin Charles,GBX, Fibronectin binding protein polypeptides.
Hk Magnus (Birmingham AL) Lindberg Kjell M. (Upsala SEX) Lindgren Per-Eric (Upsala SEX) Signs Lars C. (Uppsala SEX), Fibronectin binding protein-encoding DNA.
Hook Magnus ; Lindberg Kjell Martin,SEX ; Lindgren Per-Eric,SEX ; Signas Lars Christer,SEX, Fibronection binding protein from Streptococcus dysgalactiae.
Hk Magnus (Birmingham AL) Lindberg Kjell M. (Uppsala SEX) Wadstrm Torkel M. (Knivsta SEX), Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial.
Smith William L. (Okemos MI) DeWitt David L. (East Lansing MI), Method for the detection and/or determination of a polyvalent antigen using at least two different monoclonal antibodies.
Rodwell John D. (Yardley) McKearn Thomas J. (New Hope) Alvarez Vernon L. (Morrisville PA) Radcliffe Robert D. (Titusville NJ), Molecular recognition units.
Kogan Timothy P. ; Ren Kaijun ; Vanderslice Peter ; Beck Pamela J., Process to inhibit binding of the integrin .alpha..sub.4 .beta..sub.1 to VCAM-1 or fibronectin and cyclic peptides therefor.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.